We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Olaparib Maintenance Therapy in Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05629429
Recruitment Status : Recruiting
First Posted : November 29, 2022
Last Update Posted : November 29, 2022
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
National Taiwan University Hospital

Brief Summary:
Olaparib, a PARP inhibitor, is proven as an effective therapy for germline BRCA1/2-mutated breast cancer; however, the therapeutic efficacy for somatic mutation in BRCA1/2 or genes of homologous recombination DNA repair is unclear. Maintenance of Oalaprib can delay the disease progression in patients with BRCA1/2 mutated advanced ovarian cancer after treatment with platinum based chemotherapy. The investigators design a phase 2 study to evaluate the efficacy of maintenance of Olaparib in patients with metastatic breast cancer. The investigators enroll patients with metastatic ER(+)Her2(-) or triple-negative breast cancer. Patients who are chemotherapy-naïve or prior 1-line chemotherapy are eligible for screening. All eligible patients will receive 4 cycles of platinum based chemotherapy. Gene test will be performed on their breast tumor. If patients have mutation of HR genes and at least stable disease after platinum based chemotherapy, they will be randomized to treatment arm (Olaparib maintenance) or control arm (continuation of chemotherapy). The primary end-point is progression-free survival, and the secondary end-point is to assess the response rate, overall survival and quality of life.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: Olaparib Drug: Chemotherapy drug Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Olaparib Maintenance Therapy in Patients With Metastatic Breast Cancer Following DNA-damaging Based Chemotherapy
Estimated Study Start Date : December 12, 2022
Estimated Primary Completion Date : December 31, 2025
Estimated Study Completion Date : December 31, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Olaparib

Arm Intervention/treatment
Experimental: Arm 1: olaparib treatment
Olaparib 300mg BID PO
Drug: Olaparib
Olaparib 300mg BID PO

Active Comparator: Arm2: continuation of the chemotherapy
continuation of the current platinum based chemotherapy
Drug: Chemotherapy drug
Continue platinum based chemotherapy




Primary Outcome Measures :
  1. CT or MRI assessment [ Time Frame: 3 years ]
    Progression-free survival


Secondary Outcome Measures :
  1. Survive or death [ Time Frame: 3 years ]
    Overall survival rate

  2. CT or MRI assessment [ Time Frame: 3 years ]
    Response rate

  3. Questionnaire [ Time Frame: 3 years ]
    Quality of life



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have a life expectancy ≥ 16 weeks.
  2. Provision of informed consent prior to any study specific procedures
  3. 20 years of age or older; gender includes female and male
  4. ECOG 0-1
  5. Patients should be diagnosed as metastatic breast cancer ER(+)Her2(-) or TNBC, diagnosis could be by local hospital
  6. HER2 negative [IHC 0, 1+ or IHC 2+ with corresponding ISH non-amplified of ratio less than 2.0 or ISH nonamplified ratio less than 2.0] as per ASCO-CAP HER2 guideline recommendations 2013 (ASCO-CAP).
  7. At least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI)
  8. Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1. Postmenopausal is defined at least one of the followings: (a) Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments; (b) Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) levels in the post menopausal range for women under 50; (c) radiation- induced oophorectomy with last menses >1 year ago; (d) chemotherapy-induced menopause with >1 year interval since last menses; (f) surgical sterilisation (bilateral oophorectomy or hysterectomy)
  9. Male patients must use a condom during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception ([see appendix H for acceptable methods]) if they are of childbearing potential
  10. No more than previous 0-1 line of chemotherapy after metastasis confirmed
  11. For ER(+) breast cancer, patients should fail at least 1-line of hormone therapy (either in adjuvant setting or in metastatic cancer) before entering this study
  12. Patients should undergo 4-cycles of platinum-based chemotherapy and have a CR, PS or SD prior to randomisation.
  13. At least one measurable lesion that can be accurately assessed at baseline by computed tomography (CT) (magnetic resonance imaging [MRI] where CT is contraindicated) and is suitable for repeated assessment as per RECIST 1.1.
  14. Patients must have normal organ and bone marrow function measured within 28 days prior to randomisation as defined below:

    1. Haemoglobin (Hb) ≥10.0 g/dL
    2. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
    3. Platelet count ≥100 x 109/L
    4. Total bilirubin ≤1.5 x institutional upper limit of normal (ULN) unless the patient has documented Gilbert's Syndrome
    5. Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5x ULN
    6. Patients must have creatinine clearance (CrCl) of ≥51 mL/min estimated or measured using standard methodology at the investigating centre (i.e. Cockcroft-

Gault, MDRD, CK-EPI, EDTA or 24 hr urine):

-

Exclusion Criteria:

-

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

  1. Cytotoxic chemotherapy, hormonal or non hormonal targeted therapy within 21 days of Cycle 1 Day 1 is not permitted. Palliative radiotherapy must have been completed 21 or more days before Cycle 1 Day 1. The patient can receive a stable dose of bisphosphonates or denosumab for bone metastases, before and during the study as long as these were started at least 5 days prior to study treatment.
  2. More than 2 prior lines of cytotoxic chemotherapy for metastatic disease.

    1. Prior treatments with hormonal therapy and non hormonal targeted therapy are allowed and not counted as a prior line of cytotoxic chemotherapy.
    2. For the purposes of this protocol, the combination of "an aromatase inhibitor and everolimus" or "a hormonal therapy and CDK4/6 inhibitor" is not considered cytotoxic chemotherapy.
    3. Treatment with biologics will not be considered as prior line of therapy.
    4. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment
  3. Previous treatment with a PARP inhibitor (including olaparib)
  4. The minimum washout period for immune checkpoint blockade therapy shall be 21 days.
  5. Patients with MDS/AML or with features suggestive of MDS/AML.
  6. Patients with second primary cancer, EXCEPTIONS: adequately treated non melanoma skin cancer, curatively treated in-situ cancer of the cervix, Ductal Carcinoma in Situ (DCIS), stage 1 grade 1 endometrial carcinoma, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years prior to study entry (including lymphomas [without bone marrow involvement]).
  7. Mean resting corrected QTc interval using the Fridericia formula (QTcF) >470 msec/female patients and >450 msec for male patients (as calculated per institutional standards) obtained from 3 ECGs performed 2-5 minutes apart at study entry, or congenital long QT syndrome.
  8. Any of the following cardiac diseases currently or within the last 6 months

    1. Unstable angina pectoris
    2. Congestive heart failure ≥ Class 2 as defined by the New York Heart Association
    3. Acute myocardial infarction
    4. Conduction abnormality not controlled with pacemaker or medication (patients with a conduction abnormality controlled with pacemaker or medication at the time of screening are eligible)
    5. Significant ventricular or supraventricular arrhythmias (patients with chronic rate- controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible)
  9. Concomitant use of known strong cytochrome P (CYP) 3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg.

    ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks.

    Patient has had prescription or non-prescription drugs or other products known to be sensitive CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong inhibitors/inducers of CYP3A4 which cannot be discontinued 2 weeks prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study drug. Patients should stop using herbal medications 7 days prior to first dose of study treatment.

  10. Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  11. Persistent toxicities (≥ CTCAE grade 2) caused by previous cancer therapy, excluding alopecia.
  12. Major surgery within 2 weeks of starting study treatment: patients must have recovered from any effects of any major surgery.
  13. Immunocompromised patients, eg, patients who are known to be serologically positive for human immunodeficiency virus (HIV).
  14. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.

    a. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution CT scan or any psychiatric disorder that prohibits obtaining informed consent, and any other medical condition that, in the opinion of the Investigator, places the patient at unacceptable risk of toxicity.

  15. Patients with symptomatic uncontrolled brain metastases.

    1. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease (SD) for 28 days.
    2. Patients with a history of treated central nervous system (CNS) metastases are eligible, provided they meet all of the following criteria: Disease outside the CNS is present. No clinical evidence of progression since completion of CNS-directed therapy. Minimum of 3 weeks between completion of radiotherapy and Cycle 1 Day 1 and recovery from significant (Grade ≥3) acute toxicity with no ongoing requirement for >10 mg of prednisone per day or an equivalent dose of other corticosteroid. If on corticosteroids, the patient should be receiving a stable dose of corticosteroids, started at least 4 weeks prior to treatment.
  16. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  17. Patients with a known hypersensitivity to olaparib or any of the excipients of the products.
  18. Pregnant or breast feeding women.
  19. Patients with HBV infection and uncontrolled hepatitis are not eligible. If patients are HBV carriers (HBsAg-positive without 2.5x elevation of AST/ALT), these patients can enter study if they have baseline HBV-DNA level assessed during screening, receive prophylactic medication and regularly monitored by GI doctor. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  20. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
  21. Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable, for timing refer to inclusion criteria no.7

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05629429


Contacts
Layout table for location contacts
Contact: Po-Han Lin 886972653807 pohanlin01@gmail.com
Contact: Yu-Ting Chiu 886981020813 candy987466@gmail.com

Locations
Layout table for location information
Taiwan
Taipei Veterans General Hospital Not yet recruiting
Taipei City, Please Select, Taiwan
Contact: Chi-Cheng Huang       chishenh74@gmail.com   
Principal Investigator: Ta-Chung Chao         
National Taiwan University Hospital Recruiting
Taipei, Please Select, Taiwan, 100
Contact: Po-Han Lin    0223123456 ext 71928    pohanlin01@gmail.com   
National Taiwan University Hospital Yunlin branch Not yet recruiting
Yuanlin, Taiwan
Contact: Hsing-wu Chen       hsingwuc@gmail.com   
Principal Investigator: Hsing-wu Chen         
Sponsors and Collaborators
National Taiwan University Hospital
AstraZeneca
Layout table for additonal information
Responsible Party: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT05629429    
Other Study ID Numbers: 202202045MIPA
First Posted: November 29, 2022    Key Record Dates
Last Update Posted: November 29, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Olaparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents